Policy side:
The national top-level design released the opinions on the inheritance of traditional Chinese medicine, which has been standardized and supported from the aspects of medical insurance, medical services, payment end and so on.
Payment end:
From 2017 to 2020, the proportion of traditional Chinese medicine included in medical insurance increased year by year. In 2021, the bid winning rate of traditional Chinese medicine (84%) was higher than that of Western Medicine (53%). At the same time, at the level of medical insurance renewal, the decline of traditional Chinese medicine renewal is very mild. In addition, the opinions on the inheritance of traditional Chinese Medicine issued on December 30, 2021 proposed to give guidance on the inclusion of traditional Chinese medicine institutions and traditional Chinese medicine medical insurance, and pointed out that traditional Chinese medicine institutions may not implement DRG payment for the time being.
Declaration end:
In the updated 2020 edition of the registration classification of traditional Chinese medicine, innovative traditional Chinese medicine is listed as the first category. Among the 191 application projects in 2016-2021, the proportion of innovative traditional Chinese medicine has increased significantly year by year. The application proportion of innovative traditional Chinese medicine in 2021 was 65%, twice that in 2020 and about five times that in 2019.
Approval end:
In 2017-2020, 20 innovative traditional Chinese medicines were approved, of which 12 were approved in 2021, exceeding the total in 2017-2020. Innovative traditional Chinese medicines started rapidly.
Clinical end:
According to the available statistical data, China has carried out 905 clinical studies related to traditional Chinese medicine in recent 8 years, paying more attention to evidence-based medicine and post market re evaluation; In recent three years, with the wave of innovative drugs, the phase III clinical proportion of traditional Chinese medicine has gradually increased, and a number of international multi center studies have emerged.
Enterprise side:
Based on the development of traditional Chinese medicine innovative drugs, we combed the targets of traditional Chinese medicine innovative drugs, including: Jianmin Pharmaceutical Group Co.Ltd(600976) (covered, purchase evaluation), Guiyang Xintian Pharmaceutical Co.Ltd(002873) , Jiangsu Kanion Pharmaceutical Co.Ltd(600557) , Tasly Pharmaceutical Group Co.Ltd(600535) , Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) , Hunan Fangsheng Pharmaceutical Co.Ltd(603998) .
